Dose-dense adjuvant chemotherapy in early breast cancer patients: 15-year results of the Phase 3 Mammella InterGruppo (MIG)-1 study | British Journal of Cancer
Dose Dense-Intensive Chemotherapy Improves Survival in Early Stage Breast Cancer - CancerConnect
1869-Breast neoadjuvant AC (DOXOrubicin and CYCLOPHOSPHamide) dose dense | eviQ
Dose-dense chemotherapy in breast cancer and lymphoma - ScienceDirect
Dr Sunil Verma on Twitter: "Dr. Gray sharing data on chemotherapy schedule impact on breast cancer outcome - overall improved outcome with dose dense approach #SABCS17 https://t.co/1TvnDXVFpu" / Twitter
Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials - The Lancet
Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: A pooled analysis of the MIG1 and GIM2 phase III studies - ScienceDirect
Definitive Proof that Dose-Dense Chemotherapy Is Safe and Effective for Breast Cancer | Memorial Sloan Kettering Cancer Center
Survival benefit of pure dose-dense chemotherapy in breast cancer: a meta-analysis of randomized controlled trials | World Journal of Surgical Oncology | Full Text
Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00 - Annals of
Optimising dose-dense regimens for early breast cancer | Cancer World Archive
Myeloid Growth Factor Support for Dose-Dense Adjuvant Chemotherapy for Breast Cancer
Optimising dose-dense regimens for early breast cancer | Cancer World Archive
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial - The Lancet
Dose-dense chemotherapy in breast cancer and lymphoma - ScienceDirect
Survival outcomes for dose‐dense paclitaxel plus carboplatin neoadjuvant vs standard adjuvant chemotherapy in stage II to III triple‐negative breast cancer: A prospective cohort study with propensity‐matched analysis - Xiu - 2022 -
Optimising dose-dense regimens for early breast cancer | Cancer World Archive
PDF) Dose Dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel (Dose Dense AC Followed by T) Regimen for Breast Cancer
Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group -
Adjuvant Dose-Dense Chemotherapy in Breast Cancer: Standard of Care in High-Risk Patients | Semantic Scholar
Optimising dose-dense regimens for early breast cancer | Cancer World Archive
Dose-dense paclitaxel plus carboplatin <i>vs</i>. epirubicin and cyclophosphamide with paclitaxel as adjuvant chemotherapy for high-risk triple-negative breast cancer
Does dose-dense neoadjuvant chemotherapy have clinically significant prognostic value in breast cancer?: A meta-analysis of 3,724 patients | PLOS ONE
Does dose-dense neoadjuvant chemotherapy have clinically significant prognostic value in breast cancer?: A meta-analysis of 3,724 patients | PLOS ONE
![PDF] Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/cad0421203b35bdec3bcffd87abb3ca1fd4c1ef4/7-Figure3-1.png "PDF] Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial | Semantic Scholar")
PDF] Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial | Semantic Scholar
